# Challenges and opportunities for pancreatic cancer immunotherapy

Source: https://onco.cc/key-papers/paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020/  
OnCo record `paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020` (Key paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A review of why immune drugs fail in pancreatic cancer: the tumour's own driver genes build immune suppression from the start, single agents do nothing, and the proposed answer is to combine antigen delivery, T-cell support and stromal reprogramming.

## Summary

Pancreatic ductal adenocarcinoma is among the most immune-resistant tumour types; its genomic landscape shaped by oncogenic drivers promotes immune suppression from the earliest stages of tumour inception and subverts adaptive T-cell immunity. Single-agent immune modulators have been clinically ineffective and multi-modal therapies targeting mechanisms of resistance are likely needed. The review covers strategies to confer antigen specificity, enhance T-cell effector function and neutralise immunosuppressive elements of the tumour microenvironment.

## Fields

- Kind: Key paper
- Last checked: 2026-09-24
- Journal: Cancer Cell
- Year: 2020
- DOI: 10.1016/j.ccell.2020.08.004
- Authors: Bear AS, Vonderheide RH, O'Hara MH.
- Findings: Immune suppression in pancreatic cancer is driven by the oncogenic drivers from tumour inception.; Single-agent immune modulators are ineffective; three-part combinations are proposed.
- What it means: The clearest statement of why the corpus records so many negative immunotherapy trials here, and of the design logic behind the vaccine and agonist combinations now in trials.
- Caveats: Narrative review, not a systematic analysis.; Predates the current vaccine readouts.

## Sources

- Bear, Vonderheide and O'Hara, Cancer Cell 2020: challenges and opportunities for pancreatic cancer immunotherapy: https://doi.org/10.1016/j.ccell.2020.08.004
- PubMed: https://pubmed.ncbi.nlm.nih.gov/32946773/

## Connected records

- cancers: [Pancreatic ductal adenocarcinoma](https://onco.cc/cancers/pancreatic/)
- institutions: [Abramson Cancer Center, University of Pennsylvania](https://onco.cc/institutions/penn-abramson/)
- pathways: [Cold tumours: immune deserts and exclusion](https://onco.cc/pathways/immune-desert-exclusion/), [PD-1 / PD-L1 immune checkpoint & T-cell activation](https://onco.cc/pathways/pd1-checkpoint/), [The cancer-immunity cycle](https://onco.cc/pathways/cancer-immunity-cycle/)
- terms: [Hot vs cold tumours](https://onco.cc/terms/cold-vs-hot/), [Immune exclusion](https://onco.cc/terms/immune-exclusion/)
- people: [Robert H. Vonderheide](https://onco.cc/people/robert-vonderheide/)
- journals: [Cancer Cell](https://onco.cc/journals/cancer-cell/)

---
JSON: https://onco.cc/api/v1/entities/paper-bear-pancreatic-immunotherapy-review-cancer-cell-2020.json